Ms. Michelle Lefler reports

AURORA CANNABIS INC. RESPONDS TO PRESS RELEASE OF CURALEAF HOLDINGS, INC. REGARDING INTENTION TO LAUNCH UNSOLICITED TAKE-OVER BID

Aurora Cannabis Inc. responded today to a news release issued by Curaleaf Holdings Inc. regarding its stated intention to launch an unsolicited takeover bid for all of the issued and outstanding common shares of the company at a stated implied consideration of $4 (U.S.) per Share, consisting of 0.3463 subordinate voting share of Curaleaf plus 75 U.S. cents in cash per Aurora share.

Aurora confirms that it received letters from Curaleaf dated June 23, 2026, and July 7, 2026, outlining proposals to acquire the Aurora shares. Only the July 7, 2026, letter included any proposed financial terms, and it did not include any detail regarding the mix of cash and share consideration being proposed by Curaleaf. Aurora notes that the current proposal added a cap on the value of the consideration of $5 (U.S.) per Aurora share, which is a lower price than Aurora shares have traded as recently as Dec. 18, 2025.

The proposal was not initiated or solicited by Aurora. The board of directors of Aurora, in keeping with its fiduciary duties to act in the best interests of Aurora and all of its stakeholders, carefully considered the prior proposals from Curaleaf as it reviews any proposals received regarding potential transactions in light of other available strategic alternatives and Aurora's strategic plans. In particular, Aurora's recently completed acquisition of the Safari Flower Company builds on Aurora's global medical cannabis platform, and leverages its diversified and scaled network and strong balance sheet to build sustainable, long-term shareholder value. As noted by Curaleaf, Aurora's growing EU-GMP (European Union good manufacturing practice) cultivation and manufacturing capacity is highly strategic. Aurora continues to evaluate additional opportunities to expand this capacity and add shareholder value.

Contrary to the assertion that Aurora refused to engage, Aurora's lead independent director did correspond with Curaleaf's chief executive officer, including as recently as July 24, 2026, noting that Aurora was focused on continuing to execute on its business plan over the short to medium term and did not discourage a continuing dialogue between the parties going forward.

The board intends to form a special committee of independent directors to consider the proposal, with a view to determining the course of action that is in the best interests of the company and all stakeholders.

No decision has been made with respect to the proposal and there can be no assurance that the proposal will result in any transaction. Aurora continues to operate its business as usual while executing on its announced strategic plans.

Aurora shareholders do not need to take any action at this time. The company does not intend to make any further public comment regarding the proposal or the review process unless and until it determines that additional disclosure is in the best interests of shareholders or required by law.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia and New Zealand with a portfolio of trusted, leading brands including Aurora, MedReleaf, Pedanios, IndiMed, San Raf and Whistler Medical Marijuana Corp. With world-class GMP-certified manufacturing facilities in Canada and Germany and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis.

Aurora's common shares trade on the Nasdaq Stock Market and Toronto Stock Exchange under the symbol ACB.

We seek Safe Harbor.